Correlation Analysis Of Clinical Efficacy Of Risperidone In The Treatment Of Schizophrenia And NRG1 Genotypes

Objective:1.To investigate the clinical efficacy and influencing factors of risperidone in the treatment of schizophrenia;2.To investigate the correlation between the clinical efficacy of risperidone and NRG1 genotypes in patients with schizophrenia.Methods:Thirty-seven patients with schizophrenia were enrolled after being diagnosed by two trained psychiatrists according to the criteria for clinical diagnosis of schizophrenia in the International Classification of Diseases,10th edition(ICD-10).All the enrolled patients had not received regular medication before enrollment.After diagnosis,the same psychiatrist used the Positive and Negative Symptoms Scale(PANSS)and Personal and Social Function Rating Scale(PSP)to collect clinical data of the enrolled patients at baseline.According to the duration of untreated psychosis(DUP),the patients were divided into two groups:DUP≤1 year and DUP>1 year.Risperidone titration therapy was given to all patients for 12 weeks after enrolment,and the scales were evaluated at the 2,4,8 and 12 weeks after treatment.And 6ml of venous blood from patients was collected at baseline to extract genomic DNA,and all polymorphisms of NRG1 gene were detected by microarray genotyping technology plus by imputation.Results:1.After risperidone treatment,the PANSS total score scale,positive symptoms,negative symptoms,general psychopathological symptoms,dangerous aggressive symptoms,and PSP scale scores of the patients were significantly improved compared with baseline.all P values were<0.05.2.For patients in different DUP groups,scores of PANSS total score scale,dangerous aggressive symptoms scale and PSP scale were statistically different.P<0.05.Among them,for PANSS total score scale,the difference between groups occurred at the end of the 8th week,and the score of PANSS total score scale of DUP<1 year group was lower than that of DUP>1 year group,P<0.05.For the PSP scale,the difference between groups occurred at the end of the 8th week,and the score of PSP scale in the DUP<1year group was higher than that in the DUP>1year group,P<0.05.For the dangerous aggressive symptoms scale,the difference between groups occurred at the end of the 12th week,and the score of dangerous aggressive symptoms scale in DUP<1 year group was lower than that in DUP>1 year group,P<0.05.3.NRG1 gene polymorphism locus rs112786318 CA allele,rs1386432 G allele,rs10503904 G allele,rs17624997 A allele and rs7824856 G allele significantly were associated with the improvement in PANSS scale after risperidone treatment.The P values were<0.05.The C allele at rs546524070,the GT allele at rs150984125 and the T allele at rs2439282 were associated with better improvement of dangerous aggressive symptoms after risperidone treatment.The T allele of rs56772392 and the C allele of rs5890643 were associated with worse response of dangerous aggressive symptoms after risperidone treatment,The P values were<0.05.The CA allele at rs112786318 and the G allele at rsl386432 were associated with better improvement in positive symptoms after risperidone treatment.The C allele at rs112897446,the A allele at rs11786653,and the C allele at rs11995815 were associated with worse response of positive symptoms after risperidone treatment.The P values were<0.05.The C allele at rs10808327,C allele at rs11506112,C allele at rs142450470,T allele at rs17718751,and T allele at rs28406305 were associated with worse response of general psychopathological symptoms after risperidone treatment.The P values were<0.05.Allele A at rs12680129,allele C at rs10102889,allele C at rs16879576 and allele A at rs67592140 were associated with worse response of negative symptoms after risperidone treatment.The T allele of rs 17630934 was associated with better improvement of negative symptoms after risperidone treatment,The P values were<0.05.Conclusion:1.Risperidone significantly improved the mental symptoms and social function of patients with schizophrenia,among which.the therapeutic effects in positive symptoms.general psychopathological symptoms and dangerous aggressive symptoms were better,while the therapeutic effects in negative symptoms was worse.2.DUP correlated with the degree of improvement in PANSS general symptoms,dangerous aggressive symptoms,personal and social functions in patients with schizophrenia treated with risperidone.The longer the DUP was,the worse the symptoms of schizophrenia patients improved after risperidone treatment.3.NRG1 gene polymorphism sites correlated with the clinical efficacy of risperidone in patients with schizophrenia.